Background
X-linked hypophosphatemia (XLH) is an inherited disease of phosphate metabolism in which inactivating mutations of the Phosphate Regulating Endopeptidase Homolog, X-Linked (PHEX) gene lead to local and systemic effects including impaired growth, rickets, osteomalacia, bone abnormalities, bone pain, spontaneous dental abscesses, hearing difficulties, enthesopathy, osteoarthritis, and muscular dysfunction. Patients with XLH present with elevated levels of fibroblast growth factor 23 (FGF23), which is thought to mediate many of the aforementioned manifestations of the disease. Elevated FGF23 has also been observed in many other diseases of hypophosphatemia, and a range of animal models have been developed to study these diseases, yet the role of FGF23 in the pathophysiology of XLH is incompletely understood.
Methods
The role of FGF23 in the pathophysiology of XLH is here reviewed by describing what is known about phenotypes associated with various PHEX mutations, animal models of XLH, and non-nutritional diseases of hypophosphatemia, and by presenting molecular pathways that have been proposed to contribute to manifestations of XLH.
Results
The pathophysiology of XLH is complex, involving a range of molecular pathways that variously contribute to different manifestations of the disease. Hypophosphatemia due to elevated FGF23 is the most obvious contributor, however localised fluctuations in tissue non-specific alkaline phosphatase (TNAP), pyrophosphate, calcitriol and direct effects of FGF23 have been observed to be associated with certain manifestations.
Conclusions
By describing what is known about these pathways, this review highlights key areas for future research that would contribute to the understanding and clinical treatment of non-nutritional diseases of hypophosphatemia, particularly XLH.
The article, FGF23 and its Role in X-linked Hypophosphatemia-Related Morbidity, has been cited 58 times and has been downloaded over 12k times.
As a #medicalaffairs organisation, Medialis conducts research that puts #patients first on the agenda of the #pharmaceuticalindustry.
This is especially important for individuals living with #rarediseases, who may be especially poorly represented in #clinicaltrials and #pharmaceutical companies’ activities.
We ensure that their conditions receive the research attention necessary to improve #treatment access by aiding #medicineadoption through the generation of high quality #realworldevidence for #pharmaceuticalcompanies.
Contact us at info@medialis.co.uk to find out how our commitment to excellence in #rarediseaseresearch can improve #RWE generation for your pharmaceutical company and join us in #ImprovingHealth. See the article here: https://lnkd.in/e_-fxnPD
#clinicalstudies #clinicalresearch #pharmaceuticals #rarediseaseawareness